Trial Profile

Pivotal study of INZ-701 in pediatric patients with ENPP1 Deficiency

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 23 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs INZ-701 (Primary)
Indications Calcinosis
Focus Pharmacodynamics; Registrational
Acronyms ENERGY-4

Most Recent Events

16 May 2025 According to an Inozyme Pharma media release, first Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027.
31 Jul 2023 New trial record
26 Jul 2023 According to an Inozyme Pharma Media Release, Data from the planned ENERGY-4 trial in adolescent and adult patients with ENPP1 Deficiency may provide a basis for a supplemental marketing application.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com